openPR Logo
Press release

Pulmonary Drugs Market – Boon for Diseased Lungs

04-30-2018 12:45 PM CET | Health & Medicine

Press release from: CMI - Research Reports

Pulmonary Drugs Market – Boon for Diseased Lungs

Pulmonary drugs can treat wide range of conditions, which are included within the ambit of pulmonary diseases such as pneumonia, allergic rhinitis, pulmonary hypertension, and others. . Pulmonary drugs provide medications for all types of pulmonary diseases, which is expected to fuel market growth in near future. The World Health Organization (WHO) states that most respiratory diseases are preventable and can be treated with the help of appropriate medication. This has led to intensification of efforts for development of effective and efficient pulmonary drugs and medications. Some of the pulmonary drugs are administered with the help of devices called nebulizers or inhalers.

Request to download and view Sample Report:

The global pulmonary drugs market was valued at US$ 28.1 billion in 2016 and is expected to witness a robust CAGR of 8.1% over the forecast period (2017 - 2025).

Increasing tobacco smoking to augment market growth

Increasing incidence of Chronic Obstructive Pulmonary Disease (COPD) is directly proportional to the tobacco smoking and exposure. According to the World Health Organization (WHO) 2016, tobacco smoking is the primary cause of COPD leading to around 90% of COPD cases. The irreversible damages caused due to smoke leads to adoption of lifestyle adjustments and medical treatments that includes consumption of bronchodilators, inhaled glucocorticoids, inhaled steroids, and other pulmonary drugs to relieve the disease symptoms, thereby propelling demand for pulmonary drugs. Tobacco is major cause of death and illness across the world. The number of smokers is consistent globally and does not have a drop since a past few years. Smokers are highly susceptible to respiratory diseases such as COPD and asthma. For instance, according to the Centers of Disease Control and Prevention (CDC) the average rate of smokers in 2012 was 1 in 5 people, which was reported to be constant in the Burden of Tobacco use in the U.S. released in 2015. North America dominates the global pulmonary drugs market, owing to the increasing prescriptions of Inhaled corticosteroids (ICS) and Long-acting beta-agonists (LABA) combinational products. According to Ontario Drug Policy Research Network, 2015, ICS+LABA combination products are the second-most commonly prescribed inhaled respiratory medications for all indications in Canada, with 1.1 million prescriptions dispensed in the fourth quarter of 2013, whereas, short-acting beta-agonists (e.g., salbutamol) are the most frequently prescribed inhaled respiratory medications in Canada with 1.8 million prescriptions dispensed in the same time period.

Supportive government and non-government initiatives to accelerate the market growth

The government and non-government initiatives help patients to fight the diseases by providing sufficient medical care and education regarding the benefits of preventive measures as well as appropriate medications to curb the life threatening diseases such as COPD. For instance, in 2016, according to the World Health Organization (WHO), more than 90% of deaths were reported due to COPD in low and middle-income economies. Thus, the WHO initiated Global Alliance against Chronic Respiratory Diseases (GARD) with a vision to provide required medical treatments to patients suffering from chronic respiratory diseases in low and middle income economies.

Request a Customization:

This provision demands a significant quantity of medication that is expected to propel the pulmonary drugs market. Also, in 2015, the Bill and Melinda Gates Foundation granted a US$ 89 Mn funding to Novavax, to develop RSV F (Respiratory Syncytial Virus) Vaccine for pregnant women in low sourced countries as maternal immunization vaccine to protect respiratory infections in the children. Asia Pacific is expected to be the fastest growing region in the pulmonary drugs market, owing to the continuous marketing of new brands to consolidate and strengthen the sales of products by the manufacturers. For instance, in 2016, Lupin Limited and Novartis Healthcare Private Limited (NHPL) entered into a co-marketing agreement to promote Novartis’s Indacaterol / Glycopyrronium inhaler in India for treating COPD under the brand name of Loftair. The major players operating the global pulmonary drugs market include Sanofi SA, Meda Pharmaceuticals, Circassia Pharmaceuticals Plc., AstraZenca Plc., GlaxoSmithKline Plc., Mallinckrodt Pharmaceuticals Plc., Cheisi farmaceutici S.p.A., Zambon Company S.p.A., Alaxia SAS, and Merck Sharp & Dohme Limited.

About Coherent Market Insights:

Coherent Market Insights is a prominent market research and consulting firm offering action-ready syndicated research reports, custom market analysis, consulting services, and competitive analysis through various recommendations related to emerging market trends, technologies, and potential absolute dollar opportunity.

Contact Us:

Mr. Shah
Coherent Market Insights
1001 4th Ave,
Seattle, WA 98154
Tel: +1-206-701-6702
Visit Coherent Market Insights Blog @
Connect with us on LinkedIn @

This release was published on openPR.

Permanent link to this press release:

Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.

You can edit or delete your press release Pulmonary Drugs Market – Boon for Diseased Lungs here

News-ID: 1034672 • Views: 318

More Releases from CMI - Research Reports

PoC Platform & Technology Market Research Study for the Period (2017 - 2025)
Point of care (PoC) diagnostic devices are used to obtain diagnostic results while being close to the patient and are commonly used in doctor’s office, hospitals, and in home care settings. These devices are commonly preferred in the home care settings, as they do not require technical expertise and deliver instant feedback on various medical tests. The vast applications of POC platform and technology devices include diagnosis of chronic diseases,
Low Temperature Sterilization Equipment - Market Driver, Outlook, Key Players by …
Low Temperature Sterilization Equipment Market – Advancing Sterilization Solutions Low temperature sterilization is an effective means to exercise heat and moisture sensitive surgical instrumentation, general equipment, and implant. Low temperature sterilization is used to sterilize unique devices with complex designs or those made of heat and moisture sensitive materials. This type of equipment usually include polymers on cameras, fiber optics, flexible scopes, certain plastics or recyclable invasive medical instruments made of
Low Temperature Sterilization Equipment - Market Driver, Outlook, Key Players by …
Low temperature sterilization is one of the most commonly used technique for disinfection and sterilization of equipment that are incapable to withstand high pressures and temperature in conventional sterilization techniques such as autoclave and hot air sterilization. Thus, this technique is considered to ideal for devices such as fiber optics, flexible scopes, laryngoscopes, polymers on camera, and others. The commonly used low temperature Technology type is carried out with the
Life Cell Imaging - Market Driver, Outlook, Key Players by 2025
The global life cell imaging industry has observed a notable growth over the last few decades due to significant increase in the demand for life cell imaging techniques for the study of cancer, neuroscience and drug discovery. Cellular imaging involves use of techniques that enable the detection and analysis of cellular organelles and macromolecules through light- or electron-based microscopes. Cell imaging is rapidly evolving as new technologies are being introduced

All 5 Releases

More Releases for COPD

COPD Therapeutics Global Market Research Report 2019
COPD Therapeutics Report by Material, Application, and Geography � Global Forecast to 2022 is a professional and in-depth research report on the world's major regional market conditions, focusing on the main regions (North America, Europe and Asia-Pacific) and the main countries (United States, Germany, united Kingdom, Japan, South Korea and China). Access more details about this report at: The report firstly introduced the COPD Therapeutics basics: definitions, classifications, applications and market
COPD: Disease Insights and Market Forecasts to 2024 by Pharmascroll
“COPD: Disease Insights and Market Forecasts to 2024” report delivers an in-depth understanding of the disease, historical & forecasted epidemiology of COPD disease in the US, EU5 (Germany, France, Italy, Spain, UK), and Japan and the historical & forecasted market size, for COPD, drug wise in $ sales and patient numbers at global level and in the US, EU5 (Germany, France, Italy, Spain, UK), Australia and Canada till 2024. Geographies covered: US Germany France Italy Spain UK Japan Australia Canada Drugs
SMi's Asthma & COPD conference next week in London
SMi Group reports: Limited availability on Managers Special Discount Last call [Managers Special offer - £500 savings] on SMi's Asthma & COPD conference, taking place on 11 – 12 April in London - to Directors, Principle scientists, Senior scientists, Associate directors, Managing directors, Medical directors, Pharmaceutical experts, Group leaders, Inhalation toxicologists of: clinical pharmacology; respiratory medicine/ science; respiratory immunology; pulmonary specialty; respiratory physiology. Organisers are glad to welcome Richard Marsden, Chief Executive
Global COPD and Asthma Devices Market Size
According to a new report, Global COPD and Asthma Devices Market, published by KBV Research, The Global COPD and Asthma Devices Market attained a market size of $ 27,465.1 Million in 2015 and is expected to reach $ 39,051.4 Million by 2022 growing at a CAGR of 5.2 % CAGR during 2016 – 2022. The Asia Pacific market dominated the Global COPD and Asthma Devices Market in 2015 and would
COPD Drug Market Opportunity & Clinical Pipeline Analysis
Close to 1 Billion people worldwide suffer from respiratory or pulmonary diseases. In the respiratory therapeutic domain, Asthma and COPD are the major categories, accounting for close to 75% of the total patient for respiratory or pulmonary diseases. Chronic obstructive pulmonary disease (COPD) is a disease which progresses in the lungs and requires treatment all through the life. It is an inflammatory disorder which is characterized by obstruction in the
Global COPD inhalers Industry:-Forecast 2022
Chronic Obstructive Pulmonary Disease (COPD) is a wide term used for progressive lung diseases which includes chronic bronchitis, emphysema, refractory asthma, and some forms of bronchiectasis. The symptoms of COPD includes recurrent coughing with or without sputum, difficulty in breathing, wheezing and tightness in the chest due to the blockage of lungs’ airways. More than 70 million people in the world are suffering from COPD as of 2015, majority of